Patents Assigned to THETIS PHARMACEUTICALS LLC
-
Patent number: 11925688Abstract: The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.Type: GrantFiled: October 1, 2021Date of Patent: March 12, 2024Assignee: Thetis Pharmaceuticals LLCInventors: Frank C. Sciavolino, Gary Mathias, Michael C. Van Zandt, Gunnar Erik Jagdmann, Jr., Jessica J. Dworak
-
Publication number: 20230133085Abstract: The present invention relates to compositions comprising resolvins and their use in methods of treating cancer.Type: ApplicationFiled: October 26, 2022Publication date: May 4, 2023Applicants: Thetis Pharmaceuticals LLC, Beth Israel Deaconess Medical CenterInventors: Gary Mathias, Dipak Panigrahy, John Parkinson, Aaron Mathias, Frank C. Sciavolino
-
Patent number: 11191840Abstract: The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both. Provided are pharmaceutical compositions adapted to deliver the compounds the lower gastrointestinal tract and methods of using same as monotherapy in the treatment of inflammatory diseases or disorders of the lower gastrointestinal tract, and in combination therapy with 5-aminosalicylate.Type: GrantFiled: November 28, 2018Date of Patent: December 7, 2021Assignee: Thetis Pharmaceuticals LLCInventors: Frank C. Sciavolino, Gary Mathias, Michael C. Van Zandt, Gunnar Erik Jagdmann, Jr., Jessica J. Dworak
-
Patent number: 11135298Abstract: The present invention relates to compounds of Formulas I-IV and compositions comprising same, including pharmaceutical compositions. The compounds of Formulas I-IV represent new salt forms of specialized pro-resolving mediators (“SPMs”) which include lipoxins, resolvins, protectins, and their aspirin-triggered counterparts. The SPM salts described here contain at least one or two SPM molecules ionically bound to at least one basic function that is provided by a scaffold as described in Formulas I-IV. Also provided are methods for pharmaceutical and non-pharmaceutical uses of such compounds and compositions describing same.Type: GrantFiled: August 8, 2019Date of Patent: October 5, 2021Assignee: Thetis Pharmaceuticals LLCInventors: Frank C. Sciavolino, Gary Mathias, Michael C. Van Zandt, Gunnar Erik Jagdmann, Jr., Jessica J. Dworak
-
Patent number: 10420843Abstract: The present invention relates to compounds of Formula IV, compositions comprising same, and their use in therapy wherein A and B are each independently a specialized pro-resolving mediator (“SPM”) molecule selected from an E series resolvin, a D series resolvin, and their aspirin-triggered counterparts, and M, R1, R2, X1and X2 are as defined herein.Type: GrantFiled: November 28, 2017Date of Patent: September 24, 2019Assignee: Thetis Pharmaceuticals LLCInventors: Frank C. Sciavolino, Gary Mathias, Michael C. Van Zandt, Gunnar Erik Jagdmann, Jr., Jessica J. Dworak
-
Patent number: 10130719Abstract: The present invention relates to compounds which are salts of specialized pro-resolving mediators (referred to herein as “SPMs”) which include lipoxins, resolvins, protectins, and their aspirin-triggered counterparts. The SPM salts described here contain at least one or two SPM molecules ionically bound to at least one basic function that is provided by a scaffold moiety as described herein, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.Type: GrantFiled: June 2, 2017Date of Patent: November 20, 2018Assignee: Thetis Pharmaceuticals LLCInventors: Frank C. Sciavolino, Gary Mathias, Michael C. Van Zandt, Gunnar Erik Jagdmann, Jr., Jessica J. Dworak
-
Publication number: 20180200375Abstract: The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.Type: ApplicationFiled: June 2, 2017Publication date: July 19, 2018Applicant: Thetis Pharmaceuticals LLCInventors: Frank C. Sciavolino, Gary Mathias, Michael C. Van Zandt, Gunnar Erik Jagdmann, Jr., Jessica J. Dworak
-
Patent number: 9999626Abstract: The present invention provides compounds of Formula I and related compositions and methods.Type: GrantFiled: June 12, 2015Date of Patent: June 19, 2018Assignee: Thetis Pharmaceuticals LLCInventors: Frank C. Sciavolino, Gary Mathias
-
Patent number: 9382187Abstract: Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g., aspartate or glutamate), metformin, and polyunsaturated fatty acids, such as eicosapentaenoate or docosahexaenoate. The salts can be used in the treatment of diabetes, diabetes with concomitant dyslipidemia (e.g., high triglycerides) and diabetes exacerbated cardiovascular complications, such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke. The compounds of this invention are also useful in treating obesity.Type: GrantFiled: July 10, 2013Date of Patent: July 5, 2016Assignee: Thetis Pharmaceuticals LLCInventors: Banavara L. Mylari, Frank C. Sciavolino
-
Patent number: 9242008Abstract: The present invention relates to compound of Formula III comprising an amino acid component, a divalent metal component, and a counter-ion component, compositions containing same, and methods of use.Type: GrantFiled: October 1, 2014Date of Patent: January 26, 2016Assignee: Thetis Pharmaceuticals LLCInventors: Frank C. Sciavolino, Gary Mathias
-
Patent number: 9216951Abstract: A composition which includes a salt of metformin and the use of the composition for treatment of or use in prediabetes, diabetes, lowering triglycerides and/or other conditions in mammals.Type: GrantFiled: October 27, 2014Date of Patent: December 22, 2015Assignee: Thetis Pharmaceuticals LLCInventors: Banavara L. Mylari, Frank C. Sciavolino
-
Patent number: 9012507Abstract: A composition which includes a salt of metformin and the use of the composition for treatment of or use in prediabetes, diabetes, lowering triglycerides and/or other conditions in mammals.Type: GrantFiled: December 20, 2013Date of Patent: April 21, 2015Assignee: Thetis Pharmaceuticals LLCInventors: Banavara L. Mylari, Frank C. Sciavolino
-
Patent number: 8901107Abstract: A composition which includes a salt of metformin and the use of the composition for treatment of or use in prediabetes, diabetes, lowering triglycerides and/or other conditions in mammals.Type: GrantFiled: June 21, 2013Date of Patent: December 2, 2014Assignee: Thetis Pharmaceuticals LLCInventors: Banavara L. Mylari, Frank C. Sciavolino
-
Publication number: 20140249221Abstract: Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g., aspartate or glutamate), metformin, and polyunsaturated fatty acids, such as eicosapentaenoate or docosahexaenoate. The salts can be used in the treatment of diabetes, diabetes with concomitant dyslipidemia (e.g., high triglycerides) and diabetes exacerbated cardiovascular complications, such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke. The compounds of this invention are also useful in treating obesity.Type: ApplicationFiled: May 16, 2014Publication date: September 4, 2014Applicant: Thetis Pharmaceuticals LLCInventors: Banavara L. Mylari, Frank C. Sciavolino
-
Patent number: 8765811Abstract: Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g., aspartate or glutamate), metformin, and polyunsaturated fatty acids, such as eicosapentaenoate or docosahexaenoate. The salts can be used in the treatment of diabetes, diabetes with concomitant dyslipidemia (e.g., high triglycerides) and diabetes exacerbated cardiovascular complications, such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke. The compounds of this invention are also useful in treating obesity.Type: GrantFiled: March 15, 2013Date of Patent: July 1, 2014Assignee: Thetis Pharmaceuticals LLCInventors: Banavara L. Mylari, Frank C. Sciavolino
-
Publication number: 20140148464Abstract: Provided herein are compositions for the treatment of dry eye, comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a fatty acid salt, and methods of use thereof.Type: ApplicationFiled: November 27, 2013Publication date: May 29, 2014Applicant: Thetis Pharmaceuticals LLCInventors: Banavara L. Mylari, Frank C. Sciavolino, Gary Mathias
-
Publication number: 20140107360Abstract: A composition which includes a salt of metformin and the use of the composition for treatment of or use in prediabetes, diabetes, lowering triglycerides and/or other conditions in mammals.Type: ApplicationFiled: December 20, 2013Publication date: April 17, 2014Applicant: THETIS PHARMACEUTICALS LLCInventors: Banavara L. Mylari, Frank C. Sciavolino
-
Publication number: 20140018419Abstract: Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g., aspartate or glutamate), metformin, and polyunsaturated fatty acids, such as eicosapentaenoate or docosahexaenoate. The salts can be used in the treatment of diabetes, diabetes with concomitant dyslipidemia (e.g., high triglycerides) and diabetes exacerbated cardiovascular complications, such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke. The compounds of this invention are also useful in treating obesity.Type: ApplicationFiled: March 15, 2013Publication date: January 16, 2014Applicant: Thetis Pharmaceuticals LLCInventors: Banavara L. MYLARI, Frank C. SCIAVOLINO
-
Publication number: 20140011814Abstract: Provided herein are diamine salts of eicosapentaenoic acid and docosahexaenoic acid, processes for the preparation of such compounds, pharmaceutical compositions comprising such compounds, and the uses of such compounds as agents for treating dyslipidemia, cardiovascular diseases such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke and obesity.Type: ApplicationFiled: March 15, 2013Publication date: January 9, 2014Applicant: THETIS PHARMACEUTICALS LLCInventors: Banavara L. MYLARI, Frank C. SCIAVOLINO
-
Publication number: 20130281535Abstract: A composition which includes a salt of metformin and the use of the composition for treatment of or use in prediabetes, diabetes, lowering triglycerides and/or other conditions in mammals.Type: ApplicationFiled: June 21, 2013Publication date: October 24, 2013Applicant: THETIS PHARMACEUTICALS LLCInventors: Banavara L. Mylari, Frank C. Sciavolino